Steven D. Gore

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · Journal of Clinical Oncology · 2009 · 958 citations · Full text

Medicine, Oncology, Pharmacology +13

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Bruce D. Cheson, John M. Bennett, Hagop M. Kantarjian et al. · PubMed · 2000 · 665 citations

Medicine, Hematology, Internal Medicine +11

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Margaret O’Donnell, Martin S. Tallman, Camille N. Abboud et al. · Journal of the National Comprehensive Cancer Network · 2017 · 655 citations · Full text

Medicine, Hematology, Oncology +16

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

Thomas Prébet, Steven D. Gore, Benjamin Esterni et al. · Journal of Clinical Oncology · 2011 · 480 citations · Full text

Medicine, Hematology, Pharmacotherapy +16